Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 19, 2026, 4:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 69 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Anticoagulant Therapy Clear all
Completed Phase 4 Interventional Results available

Tailoring P2Y12 Inhibiting Therapy in Patients Requiring Oral Anticoagulation After PCI

NCT04483583
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Ticagrelor 60mg, Clopidogrel
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Sep 19, 2026, 4:53 AM EDT
Completed No phase listed Observational

Efficacy and Safety of Direct Oral Anticoagulants for the Treatment of Mural Thrombus

NCT04153591
View directory record Official record
Conditions
Acute Myocardial Infarction
Interventions
Not listed
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years and older
Enrollment
75 participants
Timeline
2019 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 12, 2021 · Synced Sep 19, 2026, 4:53 AM EDT
Completed No phase listed Observational

Predicting Bleeding Risk on Anticoagulant Therapy for Venous Thromboembolism

NCT00788736
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Not listed
Lead sponsor
Ottawa Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
2,537 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
2
States / cities
Burlington, Massachusetts • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 26, 2016 · Synced Sep 19, 2026, 4:53 AM EDT
Not listed Not applicable Interventional

Randomized Trial of COBRA PzF Stenting to Reduce Duration of Triple Therapy

NCT02594501
View directory record Official record
Conditions
Angina, Stable, Angina, Unstable, Anticoagulants
Interventions
COBRA PzF, Drug Eluting Stent
Device
Lead sponsor
CeloNova BioSciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
996 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
22
States / cities
Newark, Delaware • Jacksonville, Florida • Melbourne, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2020 · Synced Sep 19, 2026, 4:53 AM EDT
Active, not recruiting Not applicable Interventional

Amplatzer Amulet LAAO vs. NOAC

NCT04226547
View directory record Official record
Conditions
Atrial Fibrillation, Stroke, Bleeding
Interventions
Left Atrial Appendage Occlusion (Amplatzer Amulet LAA Occluder), Non-Vitamin K Oral Antagonists
Device · Drug
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
2,650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
79
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Sep 19, 2026, 4:53 AM EDT
Completed Phase 4 Interventional Results available

Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion)

NCT02100228
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Apixaban, Parenteral heparin and/or oral Vitamin K antagonist
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
63
States / cities
Birmingham, Alabama • Avondale, Arizona • Chula Vista, California + 32 more
Source: ClinicalTrials.gov public record
Updated May 22, 2018 · Synced Sep 19, 2026, 4:53 AM EDT
Completed Phase 2 Interventional Results available

Study of the Efficacy and Safety of DU-176b in Preventing Blood Clots in Patients Undergoing Total Hip Replacement

NCT00107900
View directory record Official record
Conditions
Arthroplasty, Replacement, Hip, Thrombosis
Interventions
DU-176b
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced Sep 19, 2026, 4:53 AM EDT
Completed No phase listed Observational

Global Anticoagulant Registry in the FIELD- Venous Thromboembolic Events

NCT02155491
View directory record Official record
Conditions
Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism
Interventions
Not listed
Lead sponsor
Thrombosis Research Institute
Other
Eligibility
18 Years to 99 Years
Enrollment
10,679 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Muscle Shoals, Alabama
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Sep 19, 2026, 4:53 AM EDT
Terminated Phase 3 Interventional

Long-term Treatment for Cancer Patients With Deep Venous Thrombosis or Pulmonary Embolism

NCT01164046
View directory record Official record
Conditions
Venous Thromboembolism, Neoplasms
Interventions
low molecular weight heparin, vitamin K antagonists
Drug
Lead sponsor
University Medical Center Groningen
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 2, 2014 · Synced Sep 19, 2026, 4:53 AM EDT
Completed No phase listed Observational

Outpatient Treatment of Low-Risk Venous Thromboembolism With Target Specific Anticoagulant

NCT02079584
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
Not listed
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 10, 2022 · Synced Sep 19, 2026, 4:53 AM EDT
Completed Not applicable Interventional Results available

IMplementation of an RCT to imProve Treatment With Oral AntiCoagulanTs in Patients With Atrial Fibrillation

NCT03259373
View directory record Official record
Conditions
Atrial Fibrillation, Stroke
Interventions
Early Patient-Level and Provider-Level Educational Intervention, Delayed Provider-Level Educational Intervention
Behavioral
Lead sponsor
Harvard Pilgrim Health Care
Other
Eligibility
30 Years and older
Enrollment
64,666 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
4
States / cities
Louisville, Kentucky • Quincy, Massachusetts • Waltham, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Sep 19, 2026, 4:53 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of BERIPLEX® P/N (Kcentra) Compared With Plasma in Patients With Acute Major Bleeding Caused by Anticoagulant Therapy

NCT00708435
View directory record Official record
Conditions
Blood Coagulation Disorders, Acute Major Bleeding
Interventions
Beriplex® P/N (Kcentra), Fresh frozen plasma
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
41
States / cities
Birmingham, Alabama • Los Angeles, California • San Franciso, California + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2014 · Synced Sep 19, 2026, 4:53 AM EDT
Completed No phase listed Observational

Anticoagulation Length of ThErapy and Risk of New Adverse evenTs In Venous thromboEmbolism Study

NCT03292666
View directory record Official record
Conditions
Venous Thromboembolism, Anticoagulants and Bleeding Disorders
Interventions
Oral Anticoagulant
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
39,603 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
2
States / cities
Oakland, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Nov 1, 2022 · Synced Sep 19, 2026, 4:53 AM EDT
Completed Not applicable Interventional Results available

Pharmacodynamic Effects of Dabigatran in Patients on Dual Antiplatelet Therapy

NCT01852162
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Dabigatran, Placebo
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 16, 2015 · Synced Sep 19, 2026, 4:53 AM EDT
Completed Phase 3 Interventional

Clinical Study Assessing Idrabiotaparinux Sodium Injections Once-weekly in Pulmonary Embolism Therapeutic Approach

NCT00345618
View directory record Official record
Conditions
Embolism, Thrombosis
Interventions
Idrabiotaparinux sodium, Warfarin, Placebo (for idrabiotaparinux sodium), Avidin, Placebo (for warfarin), Enoxaparin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
3,202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 20, 2016 · Synced Sep 19, 2026, 4:53 AM EDT
Completed Not applicable Interventional Results available

Anticoagulation With Enhanced Gastrointestinal Safety

NCT05563714
View directory record Official record
Conditions
Upper Gastrointestinal Bleeding, Peptic Ulcer Hemorrhage, Anticoagulant-induced Bleeding
Interventions
Clinician Notification with Nurse Facilitation (CNNF), Wait list control
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
341 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 29, 2024 · Synced Sep 19, 2026, 4:53 AM EDT
Completed Phase 4 Interventional Results available

Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease

NCT04006288
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Clopidogrel, Prasugrel, ticagrelor, aspirin, rivaroxaban
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 25, 2023 · Synced Sep 19, 2026, 4:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Supporting Use of AC Through Provider Profiling of Oral AC Therapy for AF

NCT03583008
View directory record Official record
Conditions
Atrial Fibrillation, Prescribing Practices, Anticoagulants
Interventions
Anticoagulation (AC) Intervention--Academic Detailing, Anticoagulation (AC) Intervention--Prescribing Practices
Behavioral
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 20, 2019 · Synced Sep 19, 2026, 4:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Impact of an Atrial Fibrillation Decision Support Tool (AFDST) on Thromboprophylaxis for Atrial Fibrillation

NCT02524977
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter
Interventions
Decision Support, Educational Intervention Only
Behavioral
Lead sponsor
University of Cincinnati
Other
Eligibility
Not listed
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 24, 2018 · Synced Sep 19, 2026, 4:53 AM EDT
Not listed No phase listed Observational

The DARE Warfarin CER Study

NCT03271450
View directory record Official record
Conditions
Deep Venous Thrombosis, Pulmonary Embolism
Interventions
Dabigatran: extended treatment (e.g at least 90 days), Dabigatran: extended treatment (e.g at least 180 days), Dabigatran: extended treatment (e.g at least 270 days), Apixaban: extended treatment (e.g at least 90 days), Apixaban: extended treatment (e.g at least 180 days), Apixaban: extended treatment (e.g at least 270 days), Rivaroxaban: extended treatment (e.g at least 90 days), Rivaroxaban: extended treatment (e.g at least 180 days), Rivaroxaban: extended treatment (e.g at least 270 days), Edoxaban: extended treatment (e.g at least 90 days), Edoxaban: extended treatment (e.g at least 180 days), Edoxaban: extended treatment (e.g at least 270 days), Warfarin: extended treatment (e.g at least 90 days), Warfarin: extended treatment (e.g at least 180 days), Warfarin: extended treatment (e.g at least 270 days)
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
416,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Sep 19, 2026, 4:53 AM EDT
Recruiting Phase 4 Interventional

Vitamin K for Perioperative Warfarin Management

NCT07515664
View directory record Official record
Conditions
Anticoagulant Therapy
Interventions
Vitamin K, Warfarin (standard without loading), Warfarin (standard with loading)
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 19, 2026, 4:53 AM EDT
Completed Phase 3 Interventional Results available

Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE A)

NCT00249873
View directory record Official record
Conditions
Atrial Fibrillation, Vascular Risk
Interventions
clopidogrel (SR25990C), placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
7,554 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 14, 2015 · Synced Sep 19, 2026, 4:53 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Trial of Pharmacist Management of Oral Anticoagulation THerapy in the communitY for AF

NCT04907825
View directory record Official record
Conditions
Atrial Fibrillation, Stroke
Interventions
Oral anticoagulant
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
60 Years and older
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 19, 2026, 4:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of a Double-Blind, Single Dose of PER977 Administered Alone, and Following a Single Dose of Edoxaban

NCT01826266
View directory record Official record
Conditions
Anticoagulant Reversal, Reversal of Edoxaban Induced Anticoagulation
Interventions
PER977, Placebo
Drug
Lead sponsor
Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 27, 2020 · Synced Sep 19, 2026, 4:53 AM EDT